Bharti Eye Center and Foundation, New Delhi, India.
Sci Rep. 2022 Aug 18;12(1):14100. doi: 10.1038/s41598-022-14315-6.
To report the visual and refractive outcomes of new aspheric hydrophobic acrylic monofocal intraocular lens (IOL). Retrospective case series. This study included eyes of patients who underwent routine cataract surgery for uncomplicated age-related cataract with implantation of a Aktis SP (NS-60YG; Nidek Co. Ltd., Japan) IOL and attended regular follow ups at 1 week, 1 month, 3 months, and 12 months. At each post-operative visit, ophthalmological evaluation included measurement Uncorrected (UCVA) and Best corrected visual acuity (BCVA), contrast sensitivity, posterior capsular opacification (PCO), optical aberrations, analysis of point spread function (PSF) and modulation transfer function (MTF). The study included 2102 eyes of 1358 patients aged 45 to 75 years (mean age 62.6 years ± 5.6 SD). The mean preoperative BCVA was 0.56 ± 0.26 logMAR. At 1 year follow up, the mean postoperative UCVA and BCVA were 0.11 ± 0.09 and 0.02 ± 0.03 logMAR, respectively. At the end of 6 months, around 1487 (93%) eyes had BCVA of 20/20 and better than 20/30 in 100% of the eyes. Mild posterior capsule opacification (PCO) was observed in 56 patients, but none required Nd YAG laser capsulotomy. There was reduction in ocular spherical aberration and Higher order aberrations (HOAs) as compared to pre operative. This explains better contrast sensitivity obtained by MTF and PSF values. The study shows that the Aktis SP IOL is safe, effective, and stable lens that could be inserted through 2.2 mm incision with satisfactory visual and refractive outcomes, even in late post-operative period.
报告新型非球面疏水性丙烯酸单焦点人工晶状体（IOL）的视觉和屈光结果。回顾性病例系列研究。本研究纳入了 2102 只眼的 1358 例 45 至 75 岁（平均年龄 62.6±5.6 岁）患者，这些患者均因年龄相关性白内障而接受了常规白内障手术，并植入了 Aktis SP（NS-60YG；日本尼德克株式会社）IOL，术后分别在 1 周、1 个月、3 个月和 12 个月进行定期随访。每次术后随访均进行眼科评估，包括测量未矫正（UCVA）和最佳矫正视力（BCVA）、对比敏感度、后囊混浊（PCO）、光学像差、点扩散函数（PSF）和调制传递函数（MTF）的分析。术前平均 BCVA 为 0.56±0.26 logMAR。术后 1 年平均 UCVA 和 BCVA 分别为 0.11±0.09 和 0.02±0.03 logMAR。术后 6 个月末，约 1487 只眼（93%）的 BCVA 达到 20/20 或优于 20/30，100%的眼均达到 20/30 或以上。56 例患者出现轻度后囊混浊（PCO），但无一例需要 Nd YAG 激光后囊切开术。与术前相比，眼的球差和高阶像差（HOAs）均有所降低。这解释了通过 MTF 和 PSF 值获得的更好的对比敏感度。研究表明，Aktis SP IOL 是一种安全、有效且稳定的晶状体，即使在术后晚期，也可通过 2.2mm 切口植入，获得满意的视觉和屈光效果。
